You are here: Home » Current Affairs » Coronavirus » News
Business Standard

WHO expecting more info from Bharat Biotech for Covaxin approval

Covaxin is one of the three approved vaccines that have been used in India for the country's vaccination drive for adults.

Topics
World Health Organization | Bharat Biotech | Coronavirus Vaccine

Reuters 

Bharat Biotech, Covaxin
Photo: Shutterstock

The said on Monday it expects to provide more information on its COVID-19 vaccine in a further setback to the Indian company's hopes of getting an emergency-use listing for the shot.

Without WHO's nod the two-dose Covaxin is unlikely to be accepted as a valid COVID-19 vaccine around the world. has been pursuing a WHO emergency-use listing for several months, having submitted data on a rolling basis since July.

"We are aware that many people are waiting for WHO's recommendation for (Bharat Biotech's) Covaxin to be included in the #COVID19 Emergency Use Listing, but we cannot cut corners," WHO said on Twitter.

did not immediately respond to a Reuters request for comment.

Covaxin is one of the three approved vaccines that have been used in India for the country's vaccination drive for adults.

Around 30% of about 944 million eligible adults have been fully vaccinated so far, which includes the administration of more than 112 million doses of Covaxin.

"Bharat Biotech ... has been submitting data to WHO on a rolling basis and WHO experts have reviewed these data. WHO is expecting one additional piece of information from the company today," the global health agency said on Twitter.

WHO's chief scientist Soumya Swaminathan said on Sunday the agency's technical advisory group will meet on Oct. 26 to consider the listing for Covaxin.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 18 2021. 19:18 IST
RECOMMENDED FOR YOU